X
Details:
The acquisition also provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next generation Conditionally Activated Biologics. The technology platform is highly complementary to Sanofi’s existing R&D platforms.
Lead Product(s): AMX-818
Therapeutic Area: Oncology Product Name: AMX-818
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 08, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
Under the terms of the agreement, Sanofi will acquire Amunix with it's pipeline including it's lead candidate, AMX-818, a masked HER2-directed TCE, offers a strong strategic fit with Sanofi’s focus on developing potentially transformative cancer therapies in immuno-oncology.
Lead Product(s): AMX-818
Therapeutic Area: Oncology Product Name: AMX-818
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $1,225.0 million Upfront Cash: $1,000.0 million
Deal Type: Acquisition December 21, 2021
Iran Expo
Not Confirmed
Contact Supplier
Details:
AMX-818, a protease-activated T cell engager targeting HER2 with potent T Cell activation, proteolytic cleavage and efficacy in Xenograft tumors.
Lead Product(s): AMX-818
Therapeutic Area: Oncology Product Name: AMX-818
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Iran Expo
Not Confirmed
Contact SupplierDetails:
Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid tumors.
Lead Product(s): AMX-818
Therapeutic Area: Oncology Product Name: AMX-818
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Iran Expo
Not Confirmed
Contact SupplierDetails:
Amunix plans to utilize the Series A proceeds to advance its lead development candidate, AMX-818, to progress earlier discovery stage XPAT programs and to initiate XPAC discovery work.
Lead Product(s): AMX-818
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Omega Funds
Deal Size: $73.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 04, 2020
Iran Expo
Not Confirmed
Contact SupplierDetails:
This agreement builds on Amunix’s previous technology assessment with Roche focused on using XTEN, a proprietary unstructured polypeptide, to extend drug half-life.
Lead Product(s): Polypeptides
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,540.0 million Upfront Cash: $40.0 million
Deal Type: Licensing Agreement January 10, 2020
Iran Expo
Not Confirmed
Contact Supplier
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
